Tvardi Therapeutics (TVRD) Cash from Restructuring (2024 - 2025)

Tvardi Therapeutics (TVRD) posted Cash from Restructuring of -$352000.0 for Q2 2025, down 145.07% sequentially from $781000.0 in Q1 2025.

Tvardi Therapeutics (TVRD) Cash from Restructuring (2024 - 2025) Analysis & Trends

Tvardi Therapeutics has reported Cash from Restructuring for 2 years, with the latest figure at -$352000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.66 Bn	131.80 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.52 Bn	78.53 Bn	3.93 Bn
3	Argenx Se	65.33 Bn	60.14 Bn	1.37 Bn
4	Moderna	59.76 Bn	54.62 Bn	52.00 Mn
5	BeOne Medicines	42.15 Bn	37.05 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.84 Bn	28.53 Bn	992.69 Mn
7	BioNTech SE	28.23 Bn	9.84 Bn	668.28 Mn
8	Insmed	27.52 Bn	26.36 Bn	358.27 Mn
9	Royalty Pharma	27.29 Bn	26.46 Bn	-
10	Tvardi Therapeutics	17.92 Mn	17.92 Mn	-

Download Data